Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Replimune Group, Inc. (REPL)

15.98 +0.31 (+1.98%)
At close: September 2 at 4:00:00 PM EDT
16.07 +0.09 (+0.56%)
Pre-Market: 8:09:18 AM EDT
Trade REPL on Coinbase
Chart Range Bar
Loading chart for REPL
  • Previous Close 15.67
  • Open 15.65
  • Bid 11.59 x 100
  • Ask 19.96 x 100
  • Day's Range 15.50 - 16.33
  • 52 Week Range 1.50 - 16.33
  • Volume 1,989,000
  • Avg. Volume 4,651,346
  • Market Cap (intraday) 1.506B
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) --
  • EPS (TTM) -3.21
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 19.50

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

www.replimune.com

465

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

REPL
64.40%
S&P 500 (^GSPC)
11.99%

1-Year Return

REPL
170.85%
S&P 500 (^GSPC)
19.50%

3-Year Return

REPL
18.97%
S&P 500 (^GSPC)
69.77%

5-Year Return

REPL
51.49%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue --
Earnings -73.22M
Profit Margin 0.00%

Q2

FY26

Q3

FY26

Q4

FY26

-80M
-60M
-40M
-20M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

14.00 Low
19.50 Average
15.98 Current
24.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/26/2026
Analyst JP Morgan
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 20 -> 21

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    1.48B

  • Enterprise Value

    1.39B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    13.99

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.30%

  • Return on Equity (ttm)

    -134.29%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -297.01M

  • Diluted EPS (ttm)

    -3.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    195.33M

  • Total Debt/Equity (mrq)

    105.99%

  • Levered Free Cash Flow (ttm)

    -171.67M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

15.98 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: